The 2019 Voluntary Scheme for Branded Medicines Access and Pricing (VPAS) saw the industry agreeing to make payments to the Department of Health and Social Care (DHSC).
Drastic steps need to be taken if the UK is to reverse a steep decline in medicines manufacturing in recent years, according to a cross-industry coalition.
Two top pharma companies have exited the UK's voluntary medicines pricing agreement in protest at what the industry has said is a "punitive" system of revenue clawbacks, casting doubt on th
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.